[go: up one dir, main page]

PL3157552T3 - Polipeptydy syntac i ich zastosowania - Google Patents

Polipeptydy syntac i ich zastosowania

Info

Publication number
PL3157552T3
PL3157552T3 PL15809277T PL15809277T PL3157552T3 PL 3157552 T3 PL3157552 T3 PL 3157552T3 PL 15809277 T PL15809277 T PL 15809277T PL 15809277 T PL15809277 T PL 15809277T PL 3157552 T3 PL3157552 T3 PL 3157552T3
Authority
PL
Poland
Prior art keywords
syntac polypeptides
syntac
polypeptides
Prior art date
Application number
PL15809277T
Other languages
English (en)
Inventor
Ronald D. SEIDEL III
Rodolfo J. Chaparro
Brandan S. Hillerich
Scott J. Garforth
Steven C. Almo
Original Assignee
Albert Einstein College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Of Medicine filed Critical Albert Einstein College Of Medicine
Publication of PL3157552T3 publication Critical patent/PL3157552T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15809277T 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania PL3157552T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013715P 2014-06-18 2014-06-18
EP15809277.5A EP3157552B1 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof
PCT/US2015/035777 WO2015195531A2 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
PL3157552T3 true PL3157552T3 (pl) 2020-05-18

Family

ID=54936224

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15809277T PL3157552T3 (pl) 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania
PL18212801T PL3480213T3 (pl) 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18212801T PL3480213T3 (pl) 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania

Country Status (16)

Country Link
US (5) US20170058015A1 (pl)
EP (3) EP3483179B1 (pl)
JP (4) JP6652932B2 (pl)
KR (1) KR102252119B1 (pl)
CN (3) CN113248624B (pl)
AU (3) AU2015277460B2 (pl)
CA (1) CA2947489A1 (pl)
DK (2) DK3157552T3 (pl)
ES (2) ES2767259T3 (pl)
HU (2) HUE047255T2 (pl)
IL (3) IL248979B (pl)
PL (2) PL3157552T3 (pl)
PT (2) PT3157552T (pl)
SG (2) SG10202006338UA (pl)
TW (3) TWI722576B (pl)
WO (1) WO2015195531A2 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
CA3014458A1 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN109414498A (zh) * 2016-03-03 2019-03-01 Cue生物制药公司 T细胞调节性多聚体多肽及其使用方法
AU2017266905B2 (en) * 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
JP7071288B2 (ja) * 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
KR20190045213A (ko) * 2016-08-11 2019-05-02 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 면역-조절 화합물
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
EP3565829A4 (en) * 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
EP4431109A3 (en) * 2017-03-15 2024-11-27 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
US11407806B2 (en) * 2017-04-06 2022-08-09 Albert Einstein College Of Medicine Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
WO2018227286A1 (en) * 2017-06-12 2018-12-20 Sinai Health System Allograft tolerance without the need for systemic immune suppression
CN107266581B (zh) * 2017-06-13 2021-07-09 四川大学 藏猪il-12重组质粒增强pcv2疫苗免疫佐剂的制备方法及应用
EP3679064A4 (en) * 2017-09-07 2021-06-02 Cue Biopharma, Inc. T-LYMPHOCYTE MODULATOR MULTIMER POLYPEPTIDE WITH ASSOCIATED CONJUGATION SITES AND METHODS OF USE
TW201925235A (zh) * 2017-09-07 2019-07-01 美商信號生物製藥公司 具有化學結合位點之抗原呈現多肽及其使用方法
CN111050793A (zh) * 2017-09-07 2020-04-21 库尔生物制药有限公司 多聚t细胞调节性多肽及其使用方法
CA3071881A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
US11919938B2 (en) * 2017-11-30 2024-03-05 Grifols Diagnostic Solutions Inc. Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20200135397A (ko) 2018-03-24 2020-12-02 리제너론 파마슈티칼스 인코포레이티드 펩티드-mhc 복합체에 대한 치료 항체를 생성하기 위한 유전적으로 변형된 비인간 동물, 이의 제조 방법
WO2020056152A1 (en) * 2018-09-12 2020-03-19 Chang Liu Single chain constructs
US20220016181A1 (en) * 2018-12-13 2022-01-20 Sinai Health System Immunomodulatory cells and uses thereof
EP3897746A4 (en) * 2018-12-19 2022-10-26 Cue Biopharma, Inc. MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132368A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020181062A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7691927B2 (ja) * 2019-03-06 2025-06-12 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
EP3976084A4 (en) * 2019-05-29 2023-06-21 Cue Biopharma, Inc. MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
CN114423284A (zh) * 2019-09-20 2022-04-29 库尔生物制药有限公司 T细胞调节多肽及其使用方法
CA3146917A1 (en) * 2019-10-23 2021-04-29 Anish SURI T-cell modulatory chimeric molecules and methods of use thereof
MX2022007754A (es) 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
WO2021168122A1 (en) * 2020-02-18 2021-08-26 Institute For Systems Biology Single chain trimer mhc class ii nucleic acids and proteins and methods of use
WO2021168388A1 (en) * 2020-02-21 2021-08-26 3T Biosciences, Inc. Yeast display libraries, associated compositions, and associated methods of use
WO2021178975A1 (en) * 2020-03-06 2021-09-10 Albert Einstein College Of Medicine A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity
CA3178427A1 (en) * 2020-05-12 2021-11-18 Lg Chem, Ltd. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023526723A (ja) 2020-05-12 2023-06-23 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
EP4210736A4 (en) * 2020-09-09 2024-10-23 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS AND METHODS OF USE THEREOF
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
CN112779224A (zh) * 2021-01-27 2021-05-11 河南省华隆生物技术有限公司 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用
CN112725284A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk滋养层细胞及其应用
CN112725273A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk细胞及其制备方法和应用
CN112852744A (zh) * 2021-01-27 2021-05-28 河南省华隆生物技术有限公司 一种nk滋养层细胞及其制备方法和应用
CA3209361A1 (en) * 2021-03-19 2022-09-22 Ronald D. Seidel Iii T-cell modulatory polypeptides and methods of use thereof
WO2022216974A1 (en) * 2021-04-07 2022-10-13 Repertoire Immune Medicines, Inc. Peptide-mhc-immunoglobulin multimers and methods of use thereof
US20240239869A1 (en) * 2021-05-07 2024-07-18 Institute For Systems Biology Single chain trimer mhc class i nucleic acids and proteins and methods of use
TW202322846A (zh) 2021-08-16 2023-06-16 美商再生元醫藥公司 新穎的il27受體促效劑及其使用方法
WO2023126544A1 (en) * 2022-01-03 2023-07-06 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect
WO2023205728A2 (en) * 2022-04-21 2023-10-26 Institute For Systems Biology Soluble single-chain dimers from cleavable single chain trimers
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
CN119584978A (zh) 2022-06-07 2025-03-07 再生元制药公司 用于调节t细胞活性的多特异性分子及其用途
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
WO2024182540A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. T cell activators and methods of use thereof
WO2025081106A2 (en) * 2023-10-12 2025-04-17 Vanderbilt University Nanobody vaccine compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
ES2328585T3 (es) 1993-10-25 2009-11-16 Canji, Inc. Vector de adenovirus recombinante y metodo de utilizacion.
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
EP2336167B1 (en) * 2001-03-14 2019-05-29 Dako Denmark A/S MHC molecule constructs and their uses for diagnosis and therapy
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
SI2402754T2 (sl) 2006-03-06 2023-09-29 Amunix Operating Inc. Nestrukturirani rekombinantni polimeri in njihove uporabe
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
AU2008287340A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
CN116925238A (zh) * 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
CA2887486A1 (en) 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
EP3679064A4 (en) * 2017-09-07 2021-06-02 Cue Biopharma, Inc. T-LYMPHOCYTE MODULATOR MULTIMER POLYPEPTIDE WITH ASSOCIATED CONJUGATION SITES AND METHODS OF USE
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Also Published As

Publication number Publication date
WO2015195531A2 (en) 2015-12-23
US20170058015A1 (en) 2017-03-02
TWI696633B (zh) 2020-06-21
JP2020022491A (ja) 2020-02-13
IL248979A0 (en) 2017-01-31
TW202124435A (zh) 2021-07-01
TW201946933A (zh) 2019-12-16
CA2947489A1 (en) 2015-12-23
EP3480213B1 (en) 2019-11-13
AU2021204594A1 (en) 2021-07-29
JP6652680B2 (ja) 2020-02-26
TWI795740B (zh) 2023-03-11
KR102252119B1 (ko) 2021-05-17
AU2015277460B2 (en) 2020-10-08
EP3480213A1 (en) 2019-05-08
US20210238254A1 (en) 2021-08-05
JP6995151B2 (ja) 2022-02-21
TW201613966A (en) 2016-04-16
PT3480213T (pt) 2020-02-04
WO2015195531A3 (en) 2016-02-25
IL248979B (en) 2020-06-30
CN106456733A (zh) 2017-02-22
CN113248623A (zh) 2021-08-13
DK3157552T3 (da) 2020-01-13
JP2022046544A (ja) 2022-03-23
PL3480213T3 (pl) 2020-05-18
AU2015277460A1 (en) 2016-11-24
EP3157552A4 (en) 2017-11-22
TWI722576B (zh) 2021-03-21
US20200377569A1 (en) 2020-12-03
EP3483179A1 (en) 2019-05-15
AU2021204594B2 (en) 2024-05-09
EP3157552B1 (en) 2019-10-23
PT3157552T (pt) 2020-01-22
IL275307B (en) 2022-03-01
HUE048076T2 (hu) 2020-07-28
JP2017519491A (ja) 2017-07-20
US20180282392A1 (en) 2018-10-04
IL275307A (en) 2020-07-30
ES2767259T3 (es) 2020-06-17
US20210047384A1 (en) 2021-02-18
BR112016027897A2 (pt) 2017-10-24
CN113248624B (zh) 2025-02-07
SG10202006338UA (en) 2020-08-28
JP7331075B2 (ja) 2023-08-22
IL266570A (en) 2019-07-31
JP2020072733A (ja) 2020-05-14
CN113248624A (zh) 2021-08-13
ES2770330T3 (es) 2020-07-01
CN106456733B (zh) 2021-03-16
JP6652932B2 (ja) 2020-02-26
DK3480213T3 (da) 2020-02-17
EP3483179B1 (en) 2020-09-16
AU2019203442B2 (en) 2021-04-08
IL266570B (en) 2020-06-30
KR20170030484A (ko) 2017-03-17
AU2019203442A1 (en) 2019-06-06
SG11201609876TA (en) 2017-01-27
HUE047255T2 (hu) 2020-04-28
EP3157552A2 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
IL275307B (en) Syntac polypeptides and their uses
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
DK4089113T3 (da) Polypeptider
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
EP3209192A4 (en) STEERING MICROENDOSCOPE
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
DK3099791T3 (da) Protein
IL250502A0 (en) New polypeptides
PT3337506T (pt) Combinações e suas utilizações
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3184633T3 (da) Modificeret beta-galaktosidase
HRP20182029T1 (hr) Uti-fuzijski proteini
DK3099793T3 (da) Protein
GB201410031D0 (en) Polypeptides and uses thereof
DK3412700T3 (da) Forbindelser
PL3125964T3 (pl) Środki antykoncepcyjne i pokrewne
EP3298014A4 (en) S1pr2 antagonists and uses therefor
DE202014105547U8 (de) Steckverbinder und Steckverbindung